SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects
16 references·13 citing·32 second hop
Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects (2021)Predicting Reactions to Psychedelic Drugs…Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder (2020)Effects of Psilocybin-Assiste…Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression (2018)Quality of Acute Psychedelic …Psychedelics and the essential importance of context (2018)Psychedelics and the essentia…Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences (2016)Survey study of challenging e…Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016)Rapid and sustained symptom r…Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction (2014)Pilot study of the 5-HT 2A R …Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin (2012)Neural correlates of the psyc…Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects (2011)Psilocybin occasioned mystica…Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. (2009)Preferred reporting items for…Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (2009)Preferred Reporting Items for…Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Preferred reporting items for…Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later (2008)Mystical-type experiences occ…Human hallucinogen research: guidelines for safety (2008)Human hallucinogen research: …Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance (2006)Psilocybin can occasion mysti…Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action (1998)Psilocybin induces schizophre…The file drawer problem and tolerance for null results. (1979)The file drawer problem and t…The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder (2024)The therapeutic alliance betw…The Psychedelic Future of Post-Traumatic Stress Disorder Treatment (2024)The Psychedelic Future of Pos…Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression (2024)Assessing expectancy and sugg…Treatment with psychedelics is psychotherapy: beyond reductionism (2023)Treatment with psychedelics i…Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review (2023)Treatment of Posttraumatic St…Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey (2023)Naturalistic psilocybin use i…Case analysis of long-term negative psychological responses to psychedelics (2023)Case analysis of long-term ne…Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report (2022)Psilocybin-Induced Mystical-T…Neural Mechanisms and Psychology of Psychedelic Ego Dissolution (2022)Neural Mechanisms and Psychol…Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research (2022)Assessing the risk–benefit pr…Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review (2022)Adverse events in clinical tr…A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics (2022)A neurophenomenological appro…Psychedelics and Other Psychoplastogens for Treating Mental Illness (2021)Psychedelics and Other Psycho…Artifact in behavioral research (1969)The Handbook of Social Psychology (1969)Meta-analysis of Observational Studies in Epidemiology A Proposal for Reporting (2000)Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis (2000)Estimating the reproducibility of psychological science (2015)Hallucinogens (2004)Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer (2010)Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study (2015)REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics (2019)DSM‐IV‐TR: Diagnostic and Statistical Manual of Mental Disorders (2013)"Mysticism and Philosophy" (1960)Mysticism and Philosophy (2024)The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies (2007)The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration (2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration (2009)PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation (2018)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews (2021)The Hospital Anxiety and Depression Scale (1983)Psychedelics (2016)Trial of Psilocybin versus Escitalopram for Depression (2021)Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement (1999)Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration (2007)Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement (2015)A RATING SCALE FOR DEPRESSION (1960)Manual for the State-Trait Anxiety Inventory (1970)The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults (2011)Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo (2021)Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder (2022)Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (2022)The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration (2001)Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior (2007)Psilocybin with psychological support for treatment-resistant depression: six-month follow-up (2017)
this work references cited by second hop

References

  • 2009Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement83,813 cited
  • 2009Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement63,979 cited
  • 2009Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.44,857 cited
  • 1979The file drawer problem and tolerance for null results.9,043 cited
  • 2016Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial1,696 cited
  • 2006Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance1,682 cited
  • 2020Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder1,296 cited
  • 2008Human hallucinogen research: guidelines for safety1,201 cited
  • 2012Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin1,170 cited
  • 1998Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action1,015 cited
  • 2011Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects932 cited
  • 2014Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction913 cited
  • 2008Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

901 cited
  • 2018Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression806 cited
  • 2018Psychedelics and the essential importance of context655 cited
  • 2016Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences555 cited
  • Cited by

    • 2023Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review215 cited
    • 2022Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review177 cited
    • 2021Psychedelics and Other Psychoplastogens for Treating Mental Illness166 cited
    • 2022A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics150 cited
    • 2023Treatment with psychedelics is psychotherapy: beyond reductionism119 cited
    • 2023Case analysis of long-term negative psychological responses to psychedelics108 cited
    • 2022Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report100 cited
    • 2023Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey93 cited
    • 2022Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research88 cited
    • 2024Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression87 cited
    • 2022Neural Mechanisms and Psychology of Psychedelic Ego Dissolution85 cited
    • 2024The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder81 cited
    • 2024The Psychedelic Future of Post-Traumatic Stress Disorder Treatment80 cited